Sierra Acai Company
Sierra Acai Company
Open 7 Days a Week
MonaVie Independent Distributor
Distributor Training
Shop Online
Enroll Now
Buy Wholesale and maintain an Active status for 2 months and we will refund your $39 Distributor Fee
Friends
Buy Wholesale and maintain an Active status for 2 months and we will refund your $39 Distributor Fee
14-September-2008 18:38:51 - Beta amyloid Redirected from Abeta Processing of the amyloid precursor protein amyloid beta A4 precursor protein peptidase nexin-II, Alzheimer disease Identifiers Symbol APP Alt. Symbols AD1 Entrez 351 HUGO 620 OMIM 104760 RefSeq NM_000484 UniProt P05067 Other data Locus Chr. 21 q21.2 Amyloid beta Aβ or Abeta is a peptide of 39-43 amino acids that is the main constituent of amyloid plaques in the brains of Alzheimer's disease patients. Similar plaques appear in some variants of Lewy body dementia and in inclusion body myositis, a muscle disease. Aβ also forms aggregates coating cerebral blood vessels in cerebral amyloid angiopathy. These plaques are composed of a tangle of regularly ordered fibrillar aggregates called amyloid fibers, a protein fold shared by other peptides such as prions associated with protein misfolding diseases. Research on laboratory rats suggest that the two-molecule, soluble form of the peptide is a causative agent in the development of Alzheimer's and that the two-molecule form is the smallest synaptotoxic species of soluble amyloid beta oligomer 1 2 Contents 1 Formation 2 Genetics 3 Intervention strategies 4 Measuring amyloid beta 5 External links 6 References Formation Aβ is formed after sequential cleavage of the amyloid precursor protein, a transmembrane glycoprotein of undetermined function. APP can be processed by α-, β- and γ-secretases; Aβ protein is generated by successive action of the β and γ secretases. The γ secretase, which produces the C-terminal end of the Aβ peptide, cleaves within the transmembrane region of APP and can generate a number of isoforms of 39-43 amino acid residues in length. The most common isoforms are Aβ40 and Aβ42; the shorter form is typically produced by cleavage that occurs in the endoplasmic reticulum, while the longer form is produced by cleavage in the trans-Golgi network.3 The Aβ40 form is the more common of the two, but Aβ42 is the more fibrillogenic and is thus associated with disease states. Mutations in APP associated with early-onset Alzheimer's have been noted to increase the relative production of Aβ42, and thus one suggested avenue of Alzheimer's therapy involves modulating the activity of β and γ secretases to produce mainly Aβ40.4 Genetics Autosomal-dominant mutations in APP cause herary early-onset Alzheimer's disease, likely as a result of altered proteolytic processing. Increases in either total Aβ levels or the relative concentration of both Aβ40 and Aβ42 where the former is more concentrated in cerebrovascular plaques and the latter in neuritic plaques5 have been implicated in the pathogenesis of both familial and sporadic Alzheimer's disease. Due to its more hydrophobic nature, the Aβ42 is the most amyloidogenic form of the peptide. However the central sequence KLVFFAE is known to form amyloid on its own, and probably forms the core of the fibril. The amyloid hypothesis, that the plaques are responsible for the pathology of Alzheimer's disease, is accepted by the majority of researchers but is by no means conclusively established. Intra-cellular deposits of tau protein are also seen in the disease, and may also be implicated. The oligomers that form on the amyloid pathway, rather than the mature fibrils, may be the cytotoxic species.6 Intervention strategies Researchers in Alzheimer's disease have identified five strategies as possible interventions against amyloid:7 β-Secretase inhibitors. These work to block the first cleavage of APP outside of the cell. γ-Secretase inhibitors. These work to block the second cleavage of APP in the cell membrane and would then stop the subsequent formation of Aβ and its toxic fragments. Selective Aβ-42 lowering agents. These modulate γ-secretase to reduce Aβ-42 production in favor of other shorter Aβ versions. Immunotherapies. These stimulate the host immune system to recognize and attack Aβ or provide antibodies that either prevent plaque deposition or enhance clearance of plaques. Anti-aggregation agents. These prevent Aβ fragments from aggregating or clear aggregates once they are formed.8 There is some indication that supplementation of the hormone melatonin may be effective against amyloid.910 Measuring amyloid beta There are many different ways to measure Amyloid beta. One highly sensitive method is ELISA which is an immuno-sandwich assay which utilizes a pair of antibodies that recognize Amyloid beta. Imaging compounds, notable Pittsburgh Compound-B, BTA-1, a thioflavin, can selectively bind to amyloid beta in vitro and in vivo. This technique, combined with PET imaging, has been used to image areas of plaque deposits in Alzheimer's patients. External links Online 'Mendelian Inheritance in Man' OMIM 104300 References ^ Scmid, Randolf June 2008. New clue to Alzheimer's found. Yahoo News. ^ Shankar GM, Li S, Mehta TH, Garcia-Munoz A, Shepardson NE, Smith I, Brett FM, Farrell MA, Rowan MJ, Lemere CA, Regan CM, Walsh DM, Sabatini BL, Selkoe DJ 2008. Amyloid-protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nature Medicine June 22, 2008 online. doi:10.1038/nm1782. PMID 18568035. ^ Hartmann T, Bieger SC, Brühl B, et al 1997. Distinct sites of intracellular production for Alzheimer's disease Aβ40/42 amyloid peptides. Nat. Med. 3 9: 1016-20. PMID 9288729. ^ Yin YI, Bassit B, Zhu L, Yang X, Wang C, Li YM 2007. γ-Secretase Substrate Concentration Modulates the Aβ42/Aβ40 Ratio: Implications for Alzheimer's disease. J. Biol. Chem. 282 32: 23639-44. doi:10.1074/jbc.M704601200. PMID 17556361. ^ Lue LF, Kuo YM, Roher AE, et al 1999. Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer's disease. Am. J. Pathol. 155 3: 853-62. PMID 10487842. PMC:1866907. ^ Kayed R, Head E, Thompson JL, et al 2003. Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science journal 300 5618: 486-9. doi:10.1126/science.1079469. PMID 12702875. ^ Citron M 2004. Strategies for disease modification in Alzheimer's disease. Nat. Rev. Neurosci. 5 9: 677-85. doi:10.1038/nrn1495. PMID 15322526. ^ Parker, Michael H.; Chen, Robert; Conway, Kelly A.; Lee, Daniel H. S.; Luo, Chi; Boyd, Robert E.; Nortey, Samuel O.; Ross, Tina M.; Scott, Malcolm K.; Reitz, Allen B. 2002. Synthesis of +-5,8-Dihydroxy-3R-methyl-2R-dipropylamino-1,2,3,4-tetrahydro-naphthalene: An Inhibitor of β-Amyloid1-42 Aggregation. Bioorg. Med. Chem 10 11: 3565-3569. doi:10.1016/S0968-08960200251-1. PMID 12213471. ^ Lahiri DK, Chen DM, Lahiri P, Bondy S, Greig NH November 2005. Amyloid, cholinesterase, melatonin, and metals and their roles in aging and neurodegenerative diseases. Ann. N. Y. Acad. Sci. 1056: 430-49. doi:10.1196/annals.1352.008. PMID 16387707. ^ Wang XC, Zhang YC, Chatterjie N, Grundke-Iqbal I, Iqbal K, Wang JZ June 2008. Effect of melatonin and Melatonylvalpromide on beta-amyloid and neurofilaments in N2a cells. Neurochem. Res. 33 6: 1138-44. doi:10.1007/s11064-007-9563-y. PMID 18231852. v d e Metabolic disease: amyloidosis E85, 277.3 Forms of amyloid Serum amyloid P component - Serum amyloid A - Transthyretin - Beta-2 microglobulin - Bence Jones protein/Multiple myeloma - Amyloid precursor protein/Beta amyloid - Amylin Systemic amyloidosis AL amyloidosis - AA amyloidosis - Haemodialysis-associated amyloidosis - Senile systemic amyloidosis - Finnish type amyloidosis - Familial Merranean fever Organ-limited amyloidosis heart: Cardiac amyloidosis brain: Familial amyloid neuropathy - Cerebral amyloid angiopathy - Alzheimer's disease kidney: Familial renal amyloidosis cutaneous: Primary cutaneous amyloidosis - Amyloid purpura Retrieved from http://en..org/wiki/Beta_amyloid Categories: Genes on chromosome 21 | Metabolic disorders | Molecular neuroscience | Enzymes | Integral membrane proteins | Alzheimer's disease Views Article Discussion this page History Personal tools Log in / create account Navigation Main page Contents Featured content Current events Random article Search Go Search Interaction Community portal Recent changes Contact Donate to Help Toolbox What links here Related changes Upload file Special pages Printable version Permanent link Cite this page Languages العربية Español Français Suomi This page was last modified on 21 August 2008, at 10
39 Reasons to Drink Acai Juice Every Day
What is MonaVie - Watch the 8-minute video
Discovering MonaVie Video
The Power of You Video
Effects of MonaVie Active on Antioxidant Capacity in Humans
Log into your Wholesale MonaVie Account
So many of us do not eat a balanced diet, get enough sleep, have too much stress, or are impacted with toxins and pollutants. Drinking 2 ounces of MonaVie twice a day will help your body detoxify as well as build your immune system. Its the smartest thing you can do for yourself, so start today. Buying MonaVie through our company guarantees you support 7 days a week and, if you would like to share MonaVie with your family and friends we will guide you from start to finish.
1. Click on Enroll Now (30 - 55% off retail price)
2. Pay $39 for your Wholesale ID number.
3. NO minimum order required.
4. MonaVie is delivered to your door in 3 to 5 days.